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Introduction: The relationship between pancreatitis and dyslipidaemia is
unclear and has never been studied in a South African context.
Patients and methods: A prospective evaluation of all admissions with acute
pancreatitis to a regional hospital general surgical service was performed to
ascertain its relationship to dyslipidaemia. Aetiology was determined by
history and ultrasound assessment. Disease severity was assessed using a
modified Imrie score and an organ failure score. Body mass index was
calculated. A lipid profile was obtained. Abnormal profiles were repeated.
Secondary causes of dyslipidaemia were noted. A comparison of the
demographic profile, aetiology, disease severity scores, complications and
deaths were made in relationship to the lipid profiles.
Results: From June 2001 to May 2005, there were 230 admissions, of whom
31% were women and 69% men. The median age was 38 years(range 13-
73). The pancreatitis was associated with alcohol in 146(63%), gallstones in
42(19%) and idiopathic in 27(12%). The amylase was significantly higher with
a gallstone aetiology (p< 0.001) and significantly lower when dyslipidaemia
was the aetiology(p< 0.001). The ethnic distribution was: African 41.3%;
Indian 41.3%; Coloured 12.2%; White 5.2%. Thirty five(15%) patients
developed local complications of pancreatitis and 23(10%) died.
Seventy eight(34%) of those admitted with acute pancreatitis had associated
dyslipidaemia and 152(66%) were normolipaemic at admission. The average
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body mass index was significantly higher in the dyslipidaemic group (27 vs
24,5:p = 0.004). Fourteen per cent of the admissions with dyslipidaemia had
primary and 86% secondary lipid abnormalities.There was significant ethnic
variation in the prevalence of the admissions with dyslipidaemia between the
two predominant race groups Indian 50.5% and African 17.9% (p=<0.000017)
Two patients with familial lipid abnormalities had 9 admissions despite
supervised therapy. Of the dyslipidaemic admissions, 71% had
hypertriglyceridaemia and 29% had hypercholesterolaemia. Seven of the
primary dyslipidaemias had hypertriglyceridaemia and 4
hypercholesterolaemia.
The indices of disease severity were similar in the dyslipidaemic and
normolipaemic groups and in those with hypercholesterolaemia and
hypertriglyceridaemia. There was no difference in the mortality rate between
the dyslipidaemic and normolipaemic patients (p=0.58).
In the dyslipidaemic admissions the majority of complications and all the
deaths(n=9) occurred in those with hypertriglyceridaemia (p = 0.05) or with
persistent lipid abnormalities( p = 0.003).
Conclusion:
The results showed a preponderance of the Indian ethnic group in those with
pancreatitis associated with dyslipidaemia. The average body mass index
was significantly higher in the dyslipidaemic group. Adverse outcomes in





Definition and prevalence 
Acute pancreatitis, an inflammatory condition of the pancreas associated with
elevated serum amylase and lipase is common among emergency hospital
admissions.' In 1987 there were 108 000 admissions in the United States of
America (excluding Veterans Administration affairs hospitals) with 2251
deaths. In the United Kingdom the incidence has risen by a factor of 10 from
the 1960s to the 1980's. 1 In the 1980s the incidence in the Aberdeen area of
Scotland was 242 per million. 2 There is only one hospital prevalence study in
South Africa. 3 The authors assessed 133 admissions of acute pancreatitis
over a period of 14 months.
Aetiology
In the assessment of pancreatitis, knowledge of the aetiology is important as it
may alter the course of the disease and influence immediate management
and long term outcome. Data from the USA, Western Europe and Asia show
gallstones to be the cause in 45% of cases with alcohol responsible for 35%. 1
This does vary with the population studied. In a study reported from London
alcohol was found to be the causative factor in 30% and gallstones in 29% of
patients. None were attributed to dyslipidaemia. In study from Glasgow 50.5%
were associated with gallstones and 34.1% were alcohol. 5 In Aberdeen,
gallstones were causative in 30% males and 53% females, whereas alcohol
accounted for 26.5% of males but only 3% of females. 2 In Verona(ltaly),
gallstones were aetiologically implicated in 76% of cases, alcohol 12% and
unspecified metabolic causes in 1.6% of the cases.6
4
The remainder, approximately 10% are due to a host of conditions. These
causes are detailed in Appendix A Table 1. They include the following broad
categories: metabolic abnormalities, drugs or toxins, obstruction pancreatic
duct, trauma, infections, inherited conditions, vascular abnormalities and
miscellaneous conditions. 10% of cases are considered idiopathic.' Metabolic
abnormalities are usually the first to be excluded by a lipid profile and calcium
estimation.
Prevalence of lipid abnormalities in pancreatitis 
The reported prevalence of pancreatitis related to lipid abnormalities is
variable and depends on how actively lipid abnormalities are pursued in
patients admitted with a diagnosis of acute pancreatitis and what is
considered an abnormal level. In the following studies it is not clear whether
all patients were screened for lipid abnormalities and what levels were
considered to be abnormal.
A prospective analysis by Athyros et al found a prevalence of 6.9%
pancreatitis associated with dyslipidaemia. However, this study was restricted
to those patients with hypertriglyceridaemia in excess of 10 mmol/l and
lactescent serum.' In a retrospective review over a twelve year period,
Fortson et al b found that only 1.3-3.8% had pancreatitis associated with
dyslipidaemia. In a prospective analysis in Glasgow, 50.5% were associated
with gallstones, 34.1% alcohol and 4.5% had lipid abnormalities on routine
screening s .
Farmer et al, in retrospective review, described a higher prevalence of 22% in
their cohort of 45 patients with pancreatitis associated with lipid
abnormalities 9 , while Cameron et al found 39% of their cohort to have the
combined abnormalities.10










There is a paucity of epidemiological information in the South African context.
In a cohort from Cape Town, over 14 months, the predominant aetiology was
alcohol (Figure 1) Only one patient had pancreatitis associated with
dyslipidaemia. 3
Figure 1: Aetiology in Cape Town cohort.
Diagnosis and Severity Grading 
Pancreatitis is a clinical diagnosis based on the history and physical
examination and commonly but not universally associated with an elevation in
the serum amylase in excess of twice the upper limit of a normal reference
range." In dyslipidaemic pancreatitis the amylase levels have at times been
found to be normal despite clinical and radiological evidence of pancreatitis. 12-
15 Following a diagnosis of pancreatitis, severity grading is important in
triaging patients for more intensive or specific therapies and in the comparison
6
of novel therapies and outcomes between centres. The Glasgow criteria and
the presence of organ dysfunction as proposed by Banks are commonly used
grading systems. 18 ' 17
Fortson et at found that the severity assessment of pancreatitis associated
with dyslipidaemia by the Ranson, Apache 11, Banks and Balthazar CT scan
methods to be no different from historical controls. 82 ' 87 Flowever only 18 of 70
patients is this series were assessed for severity in the dyslipidaemic group. 8
Whether dyslipidaemia influences disease severity is not addressed by
previous investigators. The prevalence and outcomes of dyslipidaemia and
pancreatitis in a South African cohort is unknown and is the focus of this






Dyslipidaemia may result from a primary genetic disorder or as a
consequence of secondary factors which may be other medical conditions,
pharmaceutical agents or toxic substances. These may be found in
combination where secondary factors reveal or exacerbate a primary disorder.
18-23
Composition of lipoproteins and metabolism 
Lipids are transported in plasma as components of lipoprotein complexes
which enables the transport of these non-polar lipid compounds through the
aqueous plasma. 18
Triglycerides and cholesterol are the major lipid constituents of plasma. Being
insoluble in water they are packaged with protein as lipoprotein particles for
transport to tissues. The lipoprotein particle has a polar surface coat and a
hydrophobic core which gives it solubility in plasma. The core contains
cholesterol ester and triglyceride and the surface comprises phospholipids,
apolipoproteins and free cholesterol. 19-23
Every lipoprotein has a minimum of 1 apolipoptrotein. These are polypeptides
serving a variety of functions in lipoprotein metabolism. They give identity to
the class of lipoprotein, serve as receptor ligands, provide lipoprotein stability
and may serve as co-factors in enzymatic processes involving lipoproteins. 19-
23
The principal apolipoproteins, their distribution and functions are enumerated
and summarized in the following table.
8
Table 2: Principal apolipoproteins and their associated Lipoproteins and
their function 23
, polipoprotein Lipoproteins Function
Secretion of VLDL from liver, structural
protein of VLDL,IDL,LDL. Ligand for LDL
receptorApo-B100 VLDL,IDL,LDL
Apo-B48 Chylomicrons Secretion of chylomicrons from intestine
Apo E
Chylomicrons,VLDL, Ligand for binding of IDL and remnants to
IDL, HDL LDL receptors and LRP
Apo-Al HDL, Chylomicrons Structural proteins of HDL.activator of LCAT
Apo-A11 HDL, Chylomicrons unknown
Apo-C11
Chylomicrons,VLDL,
IDL, HDL Activator of LPL
Apo-c111
Chylomicrons,VLDL,
IDL, HDL Inhibitor of LPL activity
Apo=apolipoprotein. VLDL=very low density lipoprotein; IDL=intermediate
density lipoprotein; LDL=low density lipoprotein; HDL=high density lipoprotein;
LRP= LDL —Receptor Protein ; LCAT= Lecithin : cholesterol acyl transferase ;
LPL=lipoprotein lipase
9
Major lipoprotein classes 
All the major lipoprotein classes comprise cholesterol, triglycerides,
phospholipids and apolipoproteins in differing concentrations and their origins
and electrophoretic patterns are summarized in the following table. 19








Chylomicron << 1.006 500-80 Dietary triglycerides Origin
VLDL <1.006 80-30 Endogenous triglycerides Pre-43
IDL 1.006 -1.019 35-25
Cholesterol esters,
triglycerides Slow pre-43
LDL 1.019 -1.063 25-18 Cholesterol esters i3
HDL 1.063 -1.210 5-12
Cholesterol esters,
phospholipids a
Lp(a) 1.055 -1.085 30 Cholesterol esters Slow pre- 13
VLDL= very low density lipoproteins
IDL= intermediate density lipoproteins
LDL= low density lipoproteins
















Major pathways of lipid metabolism 
The major pathways of lipid metabolism are depicted in Figure 2 and
discussed in subsections A, B and 022 .
Figure 2.
FREE CHOLESTEROL
CM = chylomicrons; A1, B48, 8100, B400, C11, E= apoproteins Al, B48,
B100, 8400, C11, E; NEFA = non esterified fatty acids; LPL= lipoprotein
lipase; CMR= chylomicron remnants; LRP= LDL receptor-related protein ;
HDL3/2 = high density lipoprotein 3/2; LDL = low density lipoproteins; VLDL
very low density lipoproteins; VLDLR = very low density lipoprotein receptors;
LCAT = Lecithin:Cholesterol acyl transferase ; CETP = Cholesterol ester
transfer protein
11
Synthesis and transport of exogenous lipids (Figure 2, section A)
Chylomicrons, large triglyceride-rich particles, are produced in the intestinal
epithelial cells and packaged with apolipoprotein B-48 and other lipoproteins.
These particles are released into the lymphatics and then the bloodstream.
Lipoprotein lipase, located in the endothelial cells removes triglycerides,
releasing fatty acids for tissue use. Apolipoprotein apo C-11 acts as a co-
factor. This hydrolysis results in chylomicron remnants which are taken up by
the liver. There is exchange of lipids and apolipoproteins with other classes of
li poproteins 19-22
Synthesis and transport of endogenous lipids(Figure 2, section B)
In between meals, the liver produces very low density lipoprotein(VLDL).
These triglyceride-rich particles are packaged with apolipoprotein apoB-100
along with other apolipoproteins. Hydrolysis of VLDL is also mediated by apo
C-11 producing intermediate density lipoproteins which are smaller remnants
relatively rich in cholesterol. Their predominant apolipoprotein is apo E which
is a ligand for hepatocyte uptake by the Low density lipoprotein-receptor-
related protein(LRP) and the Low density lipoprotein receptor(LDLR). Low
density lipoprotein(LDL) is the ultimate product of VLDL hydrolysis and
contains the apolipoprotein apo B-100 which is the ligand for hepatocyte
uptake of of LDL. LDL delivers cholesterol to all nucleated cells by
endocytosis through receptors that recognize apolipoprotein B-100 19-22
Reverse cholesterol transport pathway (Figure 2, section C)
High density lipoprotein(HDL) which originates from the liver functions to
circulate cholesterol from the peripheral tissues to the liver. This cholesterol is
accumulated and esterified to cholesterol esters by lecithin-cholesterol
12
acyltransferase(LCAT). Apolipoprotein apo A-1 mediates this process. These
cholesterol esters are removed in the liver by hepatocyte receptors, including
the scavenger receptor(SR-B1). Transfer of cholesterol from HDL to IDL, LDL
and VLDL occurs in the plasma in exchange for triglyceride. This is mediated
by cholesterol ester transfer protein(CETP) and is dependent on the
cholesterol ester and triglyceride load. This process results in depletion of
HDL cholesterol esters in hypertriglyceridaemia and triglyceride- rich HDL
which enhances lipolysis by hepatic lipase. This is independent of apo C-11





Dyslipidaemia refers to the disorders found in lipoprotein metabolism and can
result in premature atherosclerosis or pancreatitis. Hyperlipidaemia
emphasizes the importance of elevated lipids in the adverse consequences of
the common dyslipidaemias 18 ' 22
Classifications 
There are various classifications. The Frederickson classification, first
presented in 1965, is shown in Table 4. In using the Frederickson
classification problems may arise during the resolution of
hyperlipoproteinaemia as type V abnormalities may regress to other types i.e
IV, Ill and IIB before resolution.
24 ' 25 Hence it is no longer commonly used as a
management classification for the common dyslipidaemias.
The current trend is to classify dyslipidaemias according to their known or
suspected aetiology. These are grouped as primary or secondary lipid
disorders. 26 Table 5 enumerates the common primary dyslipidaemias and
their estimated prevalence in a European setting. Table 6 enumerates the
known lipoprotein disorders, associated Frederickson typing, the primary














































LDL = low density lipoprotein
VLDL = very low density lipoprotein
IDL = intermediate density lipoprotein.
15
Primary dyslipidaemia
Primary disorders refers to dyslipidaemia with a known familial or genetic
cause. 19-23






Mainly Hypercholesterolaemia Polygenic hypercholesterolaemia 20-80%
familial hypercholesterolaemia 0.20%











frequently called type 111 0.02%
(cholesterol typically hyperlipoproteinaemia
7.0-12.0 mmol/I)
c. Triglycerides >10.0 mmo1/1 Familial lipoprotein lipase 0.10%
deficiency or heterozygous
li poprotein lipase
mutation plus another cause for
hype -trig lyceridaennia
Raised Trigylerides alone Familial or sporadic 1 %
hypertriglyceridaemia




Secondary dyslipidaemias are associated with an identifiable secondary
cause which may be aetiological or exacerbate a primary lipid disorder and
marked hyperlipoproteinaemia is frequently the result. 19-23 Some of the
commoner secondary causes of dyslipidaemia are discussed further. Alcohol
may be associated with mild to moderate hypertriglyceridaemia (high VLDL)
or severe hypertriglyceridaemia when there is a genetic lipid disorder
(chylomicronaemia syndrome).
In diabetes mellitus, triglycerides are predominantly elevated, whereas thyroid
disease produces elevation of LDL cholesterol and less frequently
triglycerides.
Obesity predominantly causes hypertriglyceridaemia but will exacerbate any
primary disorder. Anorexia is paradoxical in that it may cause elevation of
serum cholesterol. Because of improvements in long term management, renal
disease is assuming a more important cause of secondary dyslipidaemia. In
the nephrotic syndrome the abnormality is predominantly cholesterol,
whereas chronic renal failure causes hypertriglyceridaemia which is from an
increase in both VLDL and in LDL triglycerides.
13-Blockers without intrinsic sympathomimetic activity raise triglycerides and
lower HDL cholesterol. Thiazides ,[end to increase both cholesterol and
triglycerides. Oestrogens tend to raise serum triglycerides and HDL with
androgens having the opposite effect.
Cholestatic liver disease produces hypercholesterolaemia. Later in the




Table 6: Dyslipidaemia: Elevated lipoprotein, Frederickson equivalent,
Primary disorders and secondary causes. 23
Elevated Lipoprotein Primary Disorder Secondary Disorder
Exogenous Hyperlipaemia Familial lipoprotein lipase Dysglobulinemias
(Chylomicrons) deficiency SLE
Type 1 C-11 apolipoprotein deficiency
Unclassified
Endogenous Hyperlipaemia Familial Hypertriglyceridaemia Dysglobulinaemias
(VLDL) ( mild form) SLE
Type 1V Diabetic hyperliaemia
Glycogenosis, type 1
Mixed Hyperlipaemia Familia Hypertriglyceridaemia Lipodystrophies
(VLDL + Chylomicrons) (severe form) Uremia
Type V Familia; lipiprotein lipase Hypopituitarism
deficiency Nephrotic syndrome




Hypercholesterolaemia(LDL) Familial hypercholesterolaemia Nephrotic syndrome
Type 11-a (LDL receptor defects) Hypothyroidism
Familial multiple lipoprotein-type Dysglobulinaemias
hyper ipaemia Cushing syndrome
Polyge iic hypercholesterolaemia Acute intermittent porphyria
(includes exogenous hyper-
chole sterolaemia)
Combined hyperlipidaemia Familial multiple lipoprotein-type Nephrotic syndrome
(LDL + VLDL) hyperlipaemia Hypothyroidism
Type 11-b Unclassified Dysglobulinaemias
Cushing syndrome
Remnant hyperlipidaemia Familial dysbetalipoproteinaemia Hypothyroidism
(beta-VLDL) Unclassified SLE
Type 111
Lamellar hyperlipoproteinaemia Familial lecithin: cholesterol Cholestasis(with LP-X)
(Vesicular and discoidal acyltransferase deficiency Hepatic failure(with lamellar
li poproteins) HDL)
18
Clinical Grading of Dyslipidaemia:
A simpler and more practical, management orientated classification of
Dyslipidaemias is outlined in the Table 7. This refers to a grading system that
is used in the assessment of cardiac risk and the targeting of the appropriate
therapies. It notes the predominance of cholesterol or trigycerides in
assessing dyslipidaemia. The mixed grade may be considered as mild
hypertriglyceridaemia.
Therefore, in the appraisal of the dyslipidaemias, measurement of serum
cholesterol, triglycerides, HDL-cholesterol and obtaining the LDL cholesterol
by Friedewald equation is usually :sufficient in the majority of patients. 18 ' 22
Assessing the pattern of the dyslipidaemia by these assays determines the
modes of dietary and drug therapy administered.




Moderate SevereSevere Moderate Mild
TG < 1.5 1.5 - 5 5-15 > 15
TC > 7.5 > 5.0 > 5.0 variable Variable
LDLC > 5.0 > 4.0 > 3.0 variable Variable little to none
Small dense LDL in all hypertriglyceridaemias
IDLC Negligible contribution Dysbetalipoproteinaemia
Lp(a) Negligible contribution
HDLC > 1.6 Low HDLC with
H •ertriglyceridaernia 	
LpX Cholestasis
All Units are mmols/I
TG = Triglyceride; TC = total cholesterol; IDLC = intermediate density
lipoprotein cholesterol; LDLC = low density lipoprotein cholesterol; HDLC =
high density lipoprotein cholesterol; LpX = lipoprotein X .
Dyslipidaemia in a South African context
Primary Dyslipidaemia in the South African context has been studied in its
effect on the incidence of coronary heart disease and has been found to be
commonest in the Caucasian and Indian groups, intermediate in the Coloured
19
population and low in the indigenous African population. 18 ' 27-3° In a cohort of
Black patients with diabetes, the ini -;idence of dyslipidaemia had not changed
in 25 years in an urban environment and there appeared to be no differences
according to socioeconomic positicn. 31 Familial hypercholesterolaemia is
particularly common in Afrikaners, Jews and Indians. In most white
populations this has an incidence of 1 in 500. In the Afrikaner population of
South Africa the incidence is approximately 1 in 72. 27 • 29,30 In this context the
most important and commonest dyslipidaemia is hypercholesterolaemia. The





Clinical manifestations of Acute  Pancreatitis 
In more than 90% of patients the predominant clinical feature is acute onset of
mid-epigastric pain. When alcohol is the cause, the pain usually commences
12 to 48 hours after a binge episode. With gallstone pancreatitis, the pain may
follow a large meal. Nausea and vomiting accompany the pain. This is caused
by the paralytic ileus associated with retroperitoneal inflammation. Patients
may present with a severe systemic illness without abdominal symptoms but
this is rare. This is characterised by hypotension, hypoperfusion, and mental
depression. There may be evidence of respiratory compromise and pleural
collections. Fever, tachycardia, epigastric tenderness and distension are
typical. In less than 3% of patients, severe pancreatitis may result in bluish
discolouration of the left flank (Grey Turner's sign) or in the paraumbilical
region (Cullen's sign).' Jaundice may be present as a consequence of
common bile duct obstruction caused by a gallstone or oedema. 19,20,23,32-37
Laparotomy has generally been abandoned in the initial management of acute
pancreatitis. In those with severe pain and hypotension, perforated ulcer or a
ruptured aneurysm should be considered and an erect chest radiograph and
an ultrasound may provide the necessary diagnostic information to instigate
emergency surgery. Chest and abdominal radiographs are suggestive when
they demonstrate pleural effusions basal atelectasis, a sentinel loop or the
colon cut-off sign. Diagnostic contrast-enhanced CT scan is the most
sensitive non-invasive diagnostic tool. CT scan can give conclusive evidence
of the diagnosis. The amylase or the lipase serum levels are usually elevated
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but more so in gallstone pancreatilis." There are more false positives with
the amylase and it must be remembered that 10% of patients with an amylase
over 1000IU/litre will be harbouring another diagnosis which may include
necrotic bowel. 38 If there is diagnostic doubt, a laparoscopy or laparotomy
should be performed.
Dyslipidaemia and pancreatitis 
It is generally accepted that triglycerides above 1000mg/dI(11.3 mmo1/1) cause
episodes of acute pancreatitis. This is the level at which serum becomes
lactescent. 22 Clinical observation Df patients with primary lipid abnormalities
have noted onset of acute pancreatitis with the development of lactescent
serum.
25 39-41
The association between abnormalities of lipid metabolism and pancreatitis
was first documented by Speck in 1846 42 . The clinical associations vary and
the pathogenesis is unclear. 25 They are found in association with alcohol




Furthermore the lipid abnormalities in this context have been found to be
transient abnormalities which normalise with the resolution of the pancreatitis.
However, Wilson Cox et al 50 described the relatives of a patient known to
have apolipoprotein C-11 deficiency. The kindred originated from an isolated
population on a Carribean island with significant inbreeding. The inheritance
was found to be autosomal recessive with 5 of seven homozygotes having
variable attacks of pancreatitis from the age of six years. It is not clear
whether this population was tested for familial pancreatitis due to mutations
affecting Trypsinogen activating protein. 50 The age of onset varies with the
familial dyslipidaemias. The first e pisode is frequently in childhood or early
adulthood. These variables make it difficult to establish a causal relationship.
22
The attacks of pancreatitis in this setting are no different from pancreatitis due
to other aetiological agents. There is no gender or ethnic preponderance and
obesity has not been a consistent leature. 8 ' 5° Fortson et at found
dyslipidaemic pancreatitis in both Caucasian and Black subjects and 44% of
this cohort had recurrent episodes of pancreatitis.8
23
PathophysioloqV
The triggers of the inflammation in all forms of pancreatitis are poorly
understood and the complexity of the process once intiated is shown in the
Figure 3. Premature activation of the digestive enzyme trypsinogen to trypsin
is the earliest detectable event in the pathogensis of acinar cell injury in
pancreatitis. An as yet ill-defined sequence of events results in the failure of
orderly segregation of newly synthesized zymogen granules within acinar
cells. Consequently, the lysosomal hydrolase cathepsin B co-localises with
zymogen granules and activates trypsinogen, which in turn activates other
enzymes. Extracellular/interstitial activation , perhaps by macrophages may
be the initiating event. Acinar cell injury recruits leukocytes and subsequent
cytokine production. The result is local and systemic production of
inflammatory mediators, including cytokines, complements, bradykinin, nitrous










' NITRIC OXID PAFIA0	
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Figure 3: Inflammatory cascade in acute pancreatitis
I Aetiological Factor'
I Lysosome co-localisation - Cathepshi B I
Vascular leakage ARAS MODS
IL-1,2,6,8: Interleukins 1,2,6,8. TNF: Tumor necrosis factor. PAF: Platelet
activating factor. INFa, y: Interferons a, y. 0 radicals: Oygen derived radicals.
ARDS: Adult respiratory distress syndrome. MODS: Multiple organ
dysfunction syndrome.
The mechanism by which lipid abnormalities cause pancreatitis remains
unclear. A postulation is that hydrolysis of triglycerides and phospholipids
results in excess lysolecithin and free fatty acids in the pancreatic
microvasculature. This is proposed to be the noxious agent to the acinar cells
that initiates the inflammation. 51 Alternatively, trypsinogen could be activated
by the disturbance of the microcirculation caused by damage to the vessel
endothelium of the pancreatic microcirculation as a result of the acid milieu
created by the fatty acids.51
25
Diagnosis and Severity grading
Following a diagnosis of pancreatitis, severity grading is important in triaging
patients for more intensive or specific therapies, transfer to specialist centres,
in the comparison of novel therapies and outcomes between centres ,and, in
selecting patients for inclusion within trials. Trials evaluating clinical
assessment for predicting outcome have shown sensitivities of 38-64% and a
positive predictive value of 49-100"/o. The Atlanta symposium definition of





. The criteria for the assessment of organ failure are listed.
Shock: Systolic blood pressure less than 90mm Hg
Pulmonary insufficiency: Pa02, 60 mm Hg or less
Renal failure: creatinine greater than 177p.mo1/1 after rehydration
Gastrointestinal bleeding: greater than 500m1/ 24 hours
A multifactorial scoring system for acute pancreatitis was initially proposed by
Ranson et al. 54 ' 55 They used 11 factors at admission and after 48 hours. This
system was modified by Imrie et al to 9 factors within 48hours of admission.
These Glasgow criteria were further modified by Osborne et al. They excluded
age > 55years to arrive at 8 factors. 56 The presence of 3 or more factors in the
Ranson and Glasgow criteria denotes severe disease. These have not been
evaluated for predicting disease severity beyond 48hours of admission. The
Glasgow criteria are detailed in Table 8.
26
Table 8: GLASGOW CRITERIA
Variable Cut off Level
Age > 55 years
White Blood Cell count > 15 x 10 /litre
Glucose > !0 mmol/litre
Urea > 16 mmol/litre
Arterial partial pressure of oxygen < 60 mmHg
Calcium < 2 mmol/litre
Albumin < 32 g/litre
Lactate dehydrogenase > 600 IU/litre
Aspartate or alanine aminotransferase > 100 units/litre
The Apache II scoring system is used for initial prognostication at admission
and subsequent daily assessment of recovery, disease progression or the
onset of sepsis. Multifactorial scoring systemns provide accuracy of
prognostication in the region of 70.80%. A comparison of the Apache II,
Ransons, Imrie and clinical assessment revealed the following sensitivity and
specificity at 48 hours after admission. 57 The Apache-0 attempts to factor in
obesity as a body mass index of more than 30 is associated with an increase
risk of a severe clinical outcome. 3
Table 9: Sensitivity and specificity of scoring systems 57
Sensitiviity Specificity
Clinical 66% 95%
Ranson >2 75% 68%
l mrie >2 61% 89%
Apache-II >9 75% 92%
27
Disease severity in dyslipidaemic pancreatitis 
An animal experiment has suggested that dyslipidaemia is associated with a
more intensive course of pancreati:is.
58
 Fortson et al found that the disease
severity of pancreatitis associated with dyslipidaemia to be no different from
historical controls when using the Ranson, Apache, Banks and Balthazar CT
scan methods. However only 18 of 70(26%) patients is this series were
assessed for disease severity in the dyslipidaemic group.
8 
Whether
dyslipidaemia influences disease severity has not been previously
investigated. The prevalence and outcomes of dyslipidaemia and pancreatitis
in a South African cohort is unknown and is the focus of this study.
Summary
Pancreatitis is a common cause fcr acute emergency admissions to surgical
wards. The commonest causes are alcohol and gallstones. Various scoring
systems are used to predict outcome in pancreatitis. The efficacy of these
scoring systems is similar. Two of the commonly used are the Glasgow
criteria and Organ failure.
The metabolism of lipids is a complex pathway which largely deals with the
transport and degradation of cholesterol and triglycerides. Dyslipidaemia
refers to the abnormalities in these metabolic pathways which are classified
as either primary or secondary.
Dyslipidaemia and pancreatitis have a variable association. The prevalence of
pancreatitis in a particular series depends on whether these are routinely
sought on admission. Patients with familial dyslipidaemia in particular those
with elevated chylomicrons and trglycerides are prone to attacks of
28
pancreatitis which tend to recur if the dyslipidaemia is not adequately
managed.
The diagnosis of pancreatitis in the setting of lipaemic serum may be difficult
as the serum and urine amylase may be within normal levels. However a
classical clinical presentatiton with lipaemic serum is diagnostic of
pancreatitis. If the presentation is doubtful, imaging may be helpful in arriving
at a diagnosis. At times the diagnoses have been established at laparotomy.
The treatment of dyslipidaemic pancreatitis, as with other causes of
pancreatitis, is in the main supportive with more intense monitoring reserved
for those identified with severe disease.
It is unclear as to whether the currently available predictors of outcome are
universally applicable to patients with dylipidaemic pancreatitis and whether
pancreatitis in this setting has a similar outcome to other more common




Dyslipidaemia is associated with a more severe disease and a higher
incidence of complications and deaths.
AIM:
In a mixed ethnic South African cohort with pancreatitis to:
• Determine frequency of the aetiological factors.
• Determine the frequency, type, severity and persistence of
dyslipidaemia.
• Assess for all aetiologies of dyslipidaemias
• Compare the severity and outcome variables relationship to the type,
severity and persistence of dyslipidaemias.
• Compare the clinical course of dyslipidaemic patients with





Data was prospectively collected on all admissions to Addington hospital with
a diagnosis of pancreatitis . Demographic data were initially collected and the
aetiology was ascertained.
Diagnostic tools:
Clinical presentation and serum or urine amylase were the primary diagnostic
tools. A serum amylase level of twice the upper limit of normal or an elevated
urine amylase was considered significant (normal serum amylase 25-125 u/I
and urine amylase 50-760 u/I). Imaging by ultrasound or CT scan was used
as a confirmatory or primary diagnostic investigation where indicated.
Laparotomy, when performed for diagnostic doubt in critically ill patients was
also a source of the diagnosis.
Severity assessment:
All patients were staged by a modified Glasgow criteria (less LDH) and/or the
presence of organ dysfunction(Cliiiical criteria) as evidenced by shock( blood
pressure less than 90 mmHg), pulmonary dysfunction (Pa0 2 less than 60
mmHg), renal failure (creatinine greater than 177 ilmo1/1) and gastrointestinal
bleeding (greater than 500m1/hour).
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Lipid assessment:
Patients were assessed for lipid abnormalities within 48-72 hours of
admission and those with lipid abnormalities were assessed for persistence or
resolution during the index admission. If at discharge, the lipid abnormalities
persisted, the patients were referred to an endocrine unit for further
assessment and therapy.
Lipids were measured after a 14 hour fast. Cholesterol and triglycerides were
measured by a timed endpoint method using the Beckman CX7 analyser.
Both cholesterol and triglyceride are enzymatically converted to a
quinoneimine dye. The system monitors the change in absorbance at 520
nanometers which is directly related to the concentration of the compounds in
the sample and is used to calculate and express their concentrations. HDL is
measured by a homogenous assay in which a detergent releases HDL and
this is enzymatically converted to a colour product. VLDL, LDL and
chylomicrons are inhibited by this detergent. Cholesterol is then measured by
a timed-endpoint reaction read at 560nm. LDL is calculated by the HIS
(meditech) using the following formula:
Total cholesterol only — ( (Triglyceride/2.2) + HDL)
This formula is not valid when triglycerides exceed 4.00 mmo1/1.
The reference ranges were as in Table 10.
Table 10: li o roteins and reference ranges
Lipoprotein Normal Ranges
Triglyceride 0.39-1.84 mmo1/1
Total cholesterol 3.60-5.1 mmol/l
Low density lipoprotein > 4.9 mmol/l elevated
High density lipoprotein 0.90-1.68 mmo1/1
All data were entered prospectively into an excel data base.
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Clinical outcomes assessment:
The patients with lipid abnormalities were compared to the patients without
lipid abnormalties with respect to the following variables: Body mass index,
Glasgow score 3, the development of organ dysfunction, local complications
(Pseudocyst formation, gastric outlet obstruction, jaundice, abscess
formation), ICU admission and death. These same outcomes were used in
comparing the different grades of clyslipidaemia as well as the admissions
with persistent or transient lipid abnormalities.
Body mass index:
Where feasible the height in meters and the body mass in kilograms was
determined within 48hours of admssion. The body mass index was
determined by the following formula:
Body mass index = Mass(kg)/ Hoight(m)2
Obesity was considered to be a body mass index of greater than 30.
Statistical analysis 
Statistical significance was determined by the use of the Fisher exact test (two
tailed) and a value of p < 0.05 was considered significant. Where sample size
was small and zero values present, the measures of exposure effect were
calculated using confidence intervals of 95%. Risk and odds ratios were





In the period June 2001 to May 2005, there were 230 admissions with acute
pancreatitis. The majority were ma'e with an equal number in the Indian and
African groups. Thirty four percent had associated dyslipidaemia. The majority
had alcohol as an aetiology (Tablet l).
Table 11: Descriptive summary of the cohort

















The sex and age distributions in the dyslipidaemiac and normolipaemiac
groups of admissions are summarized in table 12.
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Table 12: Gender and age distribution
Female Male Age(median:range)
Dyslipidaemia 30(38%) 48(62%) 40(15-73)
Normolipaemia 41(27%) 111(73%) 37(13-69)
Entire cohort 71(31%) 159(69%) 38.5(13-73)
Table 13: Ethnic mix of Dyslipidaemic and Non dyslipidaemic admissions
Entire cohort Dyslipidaemia Normolipaemia
African 95(41.3%) 17(17.9%) 78(82.1%)
Indian 95(41.3%) 48(50.5%) 47(49.5%)
Coloured 28(12.2%) 8(28.6%) 20(71.4%)
White 12(5.2%) 5(41.7%) 7(58.3%)
Total 230(100%)
Column 1: Total ethnic groups
Column 2 and 3: percentage of the ethnic group with dyslipidaemia and
normolipaemia
A comparison was made into the number of admissions with dyslipidaemia in
a particular ethnic group and the rest of the admissions with dyslipidaemia.
The greatest prevalence was found in the Indian ethnic group with a p-value
of 0.000008. Dyslipidaemia was the lowest in the African group with a p-value
of 0.000017. The values in the Coloured and White groups were intermediate




In the dyslipidaemic group, the serum and/or urine amylase were above
diagnostic cut off level in 72(92%) of the patients and in 147(97%) of the
normolipaemic group.
The mean amylase levels by aetiology are illustrated by Table 14.






The amylase level in the gallstones was significantly higher than the other
groups, p<0.001 and significantly lower in the lipids group p<0.001.
In 6(8%) of the dyslipidaemic group the amylase levels were within normal
range and a lipaemic serum and a typical clinical presentation was used in
making the diagnosis. In the normolipaemic group of admissions the
diagnosis was made at laparotomy in 3(2%) patients who had normal amylase
assays. In another 2(1%) patients the diagnosis was also made at laparotomy
despite raised amylase levels because of a suspicion of other causes of an
acute abdomen.
Aetiology
The variation in the aetiologies of the dyslipidaemic and the normolipaemic
groups are illustrated in Table 15.
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There was no significant difference between alcohol in the dyslipidaemic
group and the normolipaemic group(p = 0.47). Gallstones were less common
in the dyslipidaemic group as opposed to the normolipaemic group(p=0.058).
Table 15: Dyslipidaemia and aetiology
Overall Dyslipidaemia Normolipaemia
Alcohol 146(63%) 47(32.2%) 99(67.8%)
Gallstones 42(18%) 9(21.4%) 33(78.6%)
Idiopathic 20(9%) 0(0%) 20(100%)
Hyperlipidaemia 22(10%) 22(100%) 0(0%)
Total 230(100%)
Column 1: Total aetiological groups
Column 2 and 3: percentage of aetiological group with dyslipidaemia and
normolipaemia
Familial dyslipidaemia 
Of the 78 admissions with dyslipidaemia, 9(12%) were of 2 patients with
familial dyslipidaemia, representing 2 families. Both families were of Indian
origin. The family tree illustrates 2 generations of affected females in one of
the families associated with seven of these admissions (Figure 4)
Both affected generations had severe hypertriglyceridaemia and had
experienced episodes of pancrealitis.
The other patient had 3 members of the same generation affected with




Family tree of 2 generations of affected females
C) FEMALE AFFECTED   MALE UNAFFECTED
FEMALE UNAFFECTED MALE UNRELATED
Clinical Grading of the Dyslipidaemias
Fifty five (71 %) of the dyslipidaomic group had hypertriglyceridaemia and
23(29%) had hypercholesterolaemia. Sixty one percent of the
hypercholesterolaemia and 51% of the hypertriglyceridaemia were mild
elevations.
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Table 16. Clinical Grading of the dyslipidaemias
Mild Moderate Severe Total
Hypercholesterolaemia 14 3 6 23
Hypertriglyceridaemia 28 14 13 55
Primary Dyslipidaemia 
Eleven (14%) of the admissions with dyslipidaemia had primary lipid
abnormalities.
Table 17: Lipid grading of 1° dyslipidaemia
Hypercholesterolaemia Mixed Hypertriglyceridaemia
mild moderate severe mild moderate severe
3 0 0 5 0 3
Secondary Dyslipidaemia 
Sixty seven(86%) of the admissions with dyslipidaemia had secondary lipid
abnormalities. In 42 of these admissions there was a single secondary cause
for the dyslipidaemia and in 25 ad missions there was a combination of
secondary aetiologies (Table 18).
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Table 18: Secondary Dyslipidaemia.















Dyslipidaemia in Alcohol,Diabetes and Obesity
Twenty three (29%) of the admissions with dyslipidaemia and pancreatitis
were diabetic as opposed to 10(7%) in the normolipaemic group(p =
0.000003). Ten(43%) of these admissions had poor sugar control on
admission with ketoacidosis.
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In this cohort, 47(60%) of the patients with dyslipidaemia and pancreatitis
consumed alcohol as opposed to 99(65%) of patients who had normolipaemia
and pancreatitis (p = 0.467).
The clinical grading of the dyslipidaemias associated with alcohol, diabetes
and obesity are illustrated in Table 19. The majority are hypertriglyceridaemia
and associated with alcohol consumption.
The mean body mass index was significantly higher at 27 (±6) in the
dyslipidaemic group than in the non dyslipidaemic group at 24,5 (±6.20) with p
= 0.004. The assessment for differences in the number of obese admissions
(BMI>30), revealed this to be significantly higher in the dyslipidaemic group(p
= 0.031).
Table 19: Secondary dyslipidaemias and clinical grading
Hypercholesterolaemia Hypertriglyceridaemia
Mild Moderate Severe Mild Moderate Severe
Alcohol 5 1 1 17 4 4





Diabetes, Drugs 2 2 3
Alcohol, Obesity 1 2
Alcohol, Drugs 1 1 1 1 1




Total 11 3 5 24 13 11
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Other secondary dyslipidaemias 
Pregnancy, thiazide diuretics, oestrogens, hypothyroidism, renal disease: Two
admissions (3%) were also of pancreatitis associated with first trimester
pregnancies. One had transient mild hypercholesterolaemia with gallstone
related pancreatitis. The other had persistent lipid abnormalities of a mixed
nature despite spontaneous termination of the pregnancy in the first trimester.
This was considered to be a primary lipid abnormality. Six(8%) of the
dyslipidaemics used thiazide diuretics. Four of them had alcohol as an
aetiology, 1 gallstones and the other idiopathic. Five had transient
abnormalities of mild, moderate and severe hypercholesterolaemia and mixed
and moderate hypertriglyceridaemia respectively. One had persistent
hypercholesterolaem ia.
There were 8(10%) admissions associated with oestrogen use. Two had
moderate hypertriglyceridaemia ard 6 severe hypertriglyceridaemia. Seven of
these admissions were of the same patient with familial dyslipidaemia
associated with diabetes.
None of the admissions were of patients with renal disease or hypothyroidism.
Severity assessment
The number of admissions with a Glasgow score >2, organ dysfunction and
Intensive care unit admission did riot reach statistical significance between the
dyslipidaemic and normolipaemic groups(p = 0.74, p=0.3 and p=0.3
respectively). Assessment of trends showed odds ratios of 1.13; 95%
confidence interval, 0.53, 2.45; 2.36; 95% confidence interval, 1.1, 5.07 and
1.57; 95% confidence interval, 0.€6, 3.77 respectively, for the admissions with








Figure 5: Severity assessment
Complications 
In dyslipidaemic group 9(12%) developed complications and 26(17%) in the
non dyslipidaemic group with a p-value 0.27 and an odds ratio of 0.63; 95%
confidence interval, 0.28, 1.43. The trend is for dyslipidaemia to be protective
for the development of complications.
Deaths 
The comparison of deaths in the 2 groups revealed a p-value of 0.58 and a
odds ratio of 1.29; 95% confidence interval, 0.53, 3.12. There is a trend







Transient and Persistent dyslipidaemia
Some patients with dyslipidaemia were observed to have abnormalities which
resolved on discharge or at 1 month review (n= 36), and, a second group
which had persistent abnormalities (n= 31). A third group was undefined due
to death or absconding prior to complete evaluation (n=11). Lipid
measurements in this group were similar to the admissions with persistent






Figure 7: Alcohol and transient or persistent lipid abnormalities
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Table 20: Initial lipid measurements in dyslipidaemic patients expressed
in transient or persistent lipid abnormalities
Variables expressed as median and range.
Lipid abnormality Triglycerides Cholesterol HDLC LDLC
Persistent 5.5(0.7-108) 7.5(2.2-24.7) 0.98(0.2-2.1) 4.33(0.7-18.2)
Transient 1.7(0.54-14.4:i 5.6(3.5-8.4) 1.3(0.7-2.2) 3.6(1.3-6.1)
Alcohol is associated with a greater proportion of transient lipid abnormalities








Disease severity: Transient and Persistent Dyslipidaemia 
The proportion of admissions with a Glasgow score of 3 and positive
clinical criteria was insignificantly greater in the group with persistent lipid
abnormalities (p = 0.33) and (p = 0 82) respectively. There were no
admissions to the intensive care unit with transient lipid abnormalities
whereas 24% of those with persistent lipid abnormalities were admitted to the
intensive care (p = 0.002), suggesting a trend towards more severe disease in
those admissions with persistent lipid abnormalities.







Figure 9: Disease outcomes in transient and persistent lipid abnormalities
The difference in the development of complications between the 2 groups was
insignificant( p = 0.41). There were no deaths among those with transient lipid
disorders and 21% among those with persistent lipid disorders( p = 0.003).
Clinical Grading of the Dyslipidaemias, aetiology, disease severity
indices, disease outcomes and mortality
Table 21: Grading of the dyslipidaemia
Mild Moderate Severe Total
Hypercholesterolaemia 14 3 6 23
Hypertriglyceridaemia 28 14 13 55
Table 21 denotes that there were 13 admissions with Triglycerides above
15mmol/land there were 2 admissions in the moderate group with a
Triglyceride level above 10 mmo1/1(19°/0). This is the level at which
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triglycerides are considered to be a cause of the pancreatitis. Six of these
were associated with alcohol consumption, 7 were diabetic and 2 primary
abnormalities.
Clinical grading of dyslipidaemia by aetiology
Table 22: Grading of dyslipidaemia by aetiology
Hypercholesterolaemia Mixed Hypertriglyceridaemia
Total mild moderate severe mild moderate severe
Dyslipidaemia 22 2 0 2 5 5 8
Gallstones 9 5 0 2 1 1 0
Alcohol 47 7 3 2 23 7 5
In those with gallstones as an aetiology 7(78%) had hypercholesterolaemia
and 2(22%) had hypertriglyceridaemia. In those associated with alcohol
12(26%) had hypercholesterolaemia and 35(74%) had hypertriglyceridaemia

















Mild 14 1 0 1 28 3 2 1
Modera
to
3 0 2 1 14 4 2 2
Severe 6 1 0 1 13 3 5 4





In Table 23 the indices of severe disease are predominantly found in the
hypertriglyceridaemia group irrespective of the grade. The differences in the
indices between the grades of dyslipidaemia did not reach statistical
significance with the p-values illustrated above.
Table 24: Disease outcome and clinical grading
Cholesterol Complications Deaths TG Complications Deaths
Mild 14 1 0 28 0 5
Moderate 3 0 0 14 2 2
Severe 6 0 0 13 4 2
Total 23 1* 0** 55 6* 9**
* p= 0.66
**p= 0.05
Table 24 denotes that the complications and deaths were predominantly in
the group with hypertriglyceridaemia.
There were 9 deaths(12%). The deaths were among admissions who had
dyslipidaemia were located as follows: 6 deaths in patients with
hypertriglyceridaemia and alcohol as a secondary association and 3 deaths in
patients with primary hypertriglyceridaemia. The majority of the deaths(56%)
were in admissions with mild hypertriglyceridaemia. The majority of mortalities
were in the first week of admission(Table 25)
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Table 25: Patterns of mortality
Time to death
< 1 week 1-2 weeks > 2 weeks
Dyslipidaemia 7(78%) 1(11%) 1(11%)
Normolipaemia 8(57%) 2(14%) 4(29%)
Summary
Seventy eight (34%) of the admissions had dyslipidaemia associated with the
pancreatitis.
The dyslipidaemic admissions were significantly higher among Indian people
and lowest in the African group. The coloured and the White groups were
intermediate.
The amylase levels were significantly higher in the admissions with gallstones
and lowest in those with dyslipidaemia.
Differences in alcohol and gallstones aetiologies was not significant between
the dyslipidaemic and normolipaemic admissions.
The body mass index was significantly higher in the dyslipidaemic
admissions.
Familial dyslipidaemia may be associated with repeat admissions. One patient
having 8 admissions in the study period.
Alcohol was the most frequent of the secondary causes of dyslipidaemia. The
majority had hypertriglyceridaemia. In the admissions with dyslipidaemia
mortalities were located in those with hypertrigylceridaemia irrespective of the
levels.
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Diabetes was significantly more common in patients with dyslipidaemia.
Obesity was a factor in 15.4% admissions with dyslipidaemia.
The transient lipid abnormalities numbered 32(41%) and the persistent
abnormalities 46(59%). The cholesterol and triglyceride levels were
significantly higher in the admissions with persistent lipid abnormalities.
The group with persistent lipid abnormalities showed a trend towards more
severe disease by intensive care unit admission. Transient dyslipidaemia
appeared to be protective for the development of complications, and all
deaths occurred in patients with persistent dyslipidaemia.
Markers of disease severity were predominantly located in those with
hypertriglyceridaemia. All the mortalities were in admissions with
hypertriglyceridaemia. The majority of deaths were in those with mild
hypertriglyceridaemia.





This study is the first report on dyslipidaemia and pancreatitis in South Africa
within a mixed ethnic background.
In this cohort, 34% of the admissions had dyslipidaemia associated with
pancreatitis over a four year period. Six(8%) had severe
hypercholesterolaemia and 13(17%) severe hypertriglyceridaemia.
Dickson et al in a prospective trial identified 14(4.5%) of 311 adissions over a
seven year period who had dyslipidaemia on routine screening.
5
 Half of them
had major lipid abnormalities (triglycerides > 10 mmo1/1). Cameron et al found
39% of their cohort to have the combined abnormalities over a five year
period 10 . Half of them had major triglyceride abnormalities. Buch et al found
32.5% had dyslipidaemia in a prospective evaluation over an unspecified
period with 29(24.8%) with varying degrees of hyperlipidaemia(transient
elevations) and 9(7.7%) had constant hyperlipidaemia. 39 Fortson et al on the
other hand found that only 1.3-3.8% had pancreatitis associated with
dyslipidaemia in a retrospective review 8 These were patients with
hypertriglyceridaemia above 500mg/dI(5.6 mmo1/1) composed of 70 patients
from 4 institutions over a twelve year period. 39 In a cohort from Cape Town,
1 % had pancreatitis associated with dyslipidaemia. 3 The focus of their study
however was on the influence of obesity on the outcomes of acute
pancreatitis over a 6 month period. In a prospective evaluation of 246
admissions with acute pancreatits, Athyros et al found 17(6.9%) of admissions
associated with hypertriglyceridaemia of more than 1000 mg/dI(11.3 mmo1/1)7
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The prevalence in this study is in keeping with one of the prospective
evaluations cited. The cut-off values in the other studies may be the cause of
the lower prevalence figures and this makes comparison difficult.
Whether alcohol consumption as a predominant cause of pancreatitis in a
cohort influences the prevalence of dyslipidaemia and pancreatitis is unclear
as Toskes found that 75% in their series had hyperlipaemia unrelated to
alcohol ingestion. 25 Whereas Buch et al found that 73.6% and Cameron et al.
95.45% in their series had hyperlipidaemia associated with alcohol
consumption. 24 ' 39 In this study there was no difference in alcohol or gallstones
as an aetiology between the dyslipidaemic and the normolipaemic
admissions. Alcohol consumption does not appear to be a causative factor of
dyslipidaemia.
Sex, Aqe, Ethnic distribution and Obesity
The average age of 42 in patients with dyslipidaemia and pancreatitis in this
study is similar to the median age of 38 and 41 reported by Athyros 7 et al and
Fortson et al 8 respectively.
There was a females(62%) bias in the admissions with dyslipidaemia and a
male(73%) bias in those with normolipaemia.
The dyslipidaemic group is predominated by the Indian ethnic group (62%)
whereas Africans are the majority in the normolipaemic group.
In the studies cited in Table 26 Caucasians and males are the majority in
admissions with dyslipidaemia.
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Table 26 : sex, alcohol and ethnic distribution dyslipidaemic
pancreatitis. 5,8,24
Sex % alcohol Ethnicity
Author Male Female Dyslipidaemia Normolipaemia Caucasian Black
Dickson 92.90% 7.10% 85.70% ns ns ns
Cameron 77.30% 12.70% 94.50% ns 63.60% 36.40%
Fortson 51.40% 48.60% 23% ns 71.40% 28.60%
ns: the respective values were not stated
Obesity and dyslipidaemic pancreatitis 
The average body mass index was significantly higher in the dyslipidaemic
group of admissions(p=0.031).
Obesity has not been a consistent feature in previous studies of dyslipidaemia
and pancreatitis.
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 and it has not been actively sought. However, obesity
has been described as a marker of severe outcome in pancreatitis 3 and the
Apache-II score was modified to the Apache-0 scoring system to factor in
obesity in severity assessment. 69
Diagnosis 
The serum amylase levels was normal in 6(8%) of the admissions of patients
with dyslipidaemia and pancreatitis and 3(2%) of admissions with
normolipaemia and pancreatitis which is insignificant.
In the 6 admissions with dyslipidaemia and normal lipids the diagnosis was
achieved by the clinical presentation and lipaemic serum. Imaging was not
used to confirm the diagnosis and none were diagnosed at surgery.
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In those with normolipaemia the diagnosis was established at surgery
performed because of clinical suspicion of other causes of an acute abdomen.
In previous studies the experience with amylase as a confirmatory test varies.
Buch et al found a tendency to lower serum amylase levels in the
dyslipidaemic group. Amylase assays confirmed the diagnosis in all
instances."
Athyros et al found amylase levels increased less than 3-fold normal in 47%
and above 3-fold normal in the rest of patients in their series. Acute
pancreatitis was confirmed by ultrasound or CT scan in those with less than 3-
fold normal amylase levels which was their cut-off point in confirming a
diagnosis of pancreatitis. 7
Warshaw et al found that serum dilution produced an increase in amylase
activity in those patients with pancreatitis associated with
hypertriglyceridaemia. Serum dilution resulted in amylase levels which
confirmed the diagnosis when the initial undiluted serum assays were within
normal limits. This rise in serum activity was found in 5 patients with
pancreatitis and a mean triglyceride level of 6100mg/dI(68.8 mmo1/1) and not
in controls without pancreatitis with a mean level of 2200mg/dI(24.8 mmo1/1) 13
This increase in amylase activity was also found in urine dilution. They
proposed the use of dilution of serum and urine to assess for increased
amylase activity. Since urine does not contain triglycerides, the inhibition of
amylase activity was thought to be another unknown factor. 13
The number of admissions with a diagnostic dilemma in this series have been
limited and the clinical picture with lipaemia was used for arriving at a
diagnosis. Serum dilution was not used to unravel amylase levels below the
cut-off level as suggested by Warshaw et al.
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The serum amylase levels were significantly higher and lower in the gallstone
pancreatitis and dyslipidaemic groups respectively when comparing amylase
levels associated with gallstones, alcohol and dyslipidaemia. The comparison
between amylase levels in pancreatitis with these three associations has not
been reported before.
Familial Dvslipidaemia 
Nine of the 78(12%) admissions with dyslipidaemia were of 2 patients with
familial dyslipidaemia, suggesting that these patients are prone to recurrent
attacks of pancreatitis. These were of Indian descent and none of them traced
onset of symptoms to childhood. In between attacks the lipid abnormalities
remained abnormal and there was difficulty in controlling the dyslipidaemia
despite supervised dietary and optimal medical management.
In other reports, patients with familial lipid abnormalities have been noted to
develop episodes of pancreatitis in childhood or early adult Hem The
pancreatitis also tended to be relapsing with persistent lipid abnormalities
between attacks. Dietary control of lipids has been reported to alter this
cycle40 . However there are no studies which assess the efficacy of medical
therapy and dietary manipulation in preventing further attacks of pancreatitis.
Management of dyslipidaemia entails control of any reversible secondary
factors (eg. Alcohol excess, diabetes). Dietary measures are aimed at
restricting fat intake and maintaining an ideal body weight (BMI< 27 kg/m2.
Drug therapy depends on the predominace of triglycerides or cholesterol in
the lipid profile. Fibrates in hypertriglyceridaemia, statins in
hypercholesterolaemia or a combination when there is a mixed picture being
the the mainstay of drug thera py21,26
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Wilson Cox et al described a cohort with familial dyslipidaemia due to
apolipoprotein C-11 deficiency. Some had attacks of pancreatitis from the age
of six years. 5° There was no report on the success of dietary and medical
therapy in preventing relapses or on the long-term outcome.
None of the patients in this series dated the first onset of symptoms to
childhood and the testing of a third generation 13 year old revealed normal
lipids.
Athyros et al described 8 of 17(47%) of patients with familial
hypertriglyceridaemia and pancreatitis. One(6%) with familial
hypercholesterolaemia and another(6%) familial combined hyperlipidaemia.
One had relapses in the longterm due to neglect of dietary and medical
therapy.'
There remains insufficient evidence from the previous reports of the efficacy
of supervised dietary and medical therapy in preventing relapses. This aspect
of the management of pancreatitis associated with dyslipidaemia has been
scantily reported and has not been the focus of previous reports of
dyslipidaemia and pancreatitis.
Secondary Dyslipidaemia and Pancreatitis 
Alcohol, dyslipidaemia and pancreatitis
The relationship between alcohol consumption, dyslipidaemia and pancreatitis
is controversial. Hypertriglyceridaemia which is composed of endogenous
triglycerides is kwown to develop after acute alocohol intake in both alcoholics
and non-alcoholics and hypertriglyceridaemia is also known to trigger attacks
of pancreatitis. In assessing whether alcohol consumption was associated
57
with an increased prevalence of dyslipidaemia, Lifton and Scheig found that
26% of alcoholics had elevated triglycerides as opposed to 15% of controls 61
In this study there was no significant difference in alcohol consumption
between the dyslipidaemic and the normolipaemic admissions.
Alcohol was a secondary consideration in 60% of the admissions with
dyslipidaemia. The majority of dyslipidaemic admissions associated with
alcohol consumption were transient hypertriglyceridaemias.
The study by Buch et al noted that alcohol played a role in more than 75% of
their patients with pancreatitis, but there was no difference in the prevalence
of alcohol between the dyslipidaemic and normolipaemic patients. 39
Fortson et al found that a lower number, 23% of dyslipidaemic pancreatitis
patients consumed alcohol in their series. No contrast was made with
normolipaemic pancreatitis. 8 Toskes reported that 75% of their series had
hyperlipidaemia and pancreatitis not asspciated with alcohol consumption.
In a contrasting finding, Dickson et al found only 4.5% to have lipid
abnormalities when presenting with acute pancreatitis, of whom 86%
consumed excessive alcohol. Continuous monitoring of this group found that
resolution of the dyslipidaemia in association with alcohol abstinence in 43%
and persistent dyslipidaemia in 36% associated with persistent alcohol
consumption. This was presented as evidence that alcohol consumption was
responsible for elevated lipids in acute pancreatitis in their series5
Buch et al found insignificant changes in the triglycerides on continuous
monitoring of their group. These patients had persistent lipid abnormalities
irrespective of abstainance from alcohol. 39 The evidence in this series was for
a pre-existing dyslipidaemia.
58
This study has not examined the outcome of the dyslipidaemia after discharge
from hospital, but the majority of dyslipidaemias associated with alcohol
consumption resolved prior to discharge and may well have been secondary
to alcohol consumption or the pancreatitis in this transient group.
Diabetes, dyslipidaemia and pancreatitis
In this study and in contrast with dyslipidaemic pancreatitis associated with
alcohol the majority of admissions associated with diabetes (70%) had
persistent lipid abnormalities at discharge. In this cohort 26% of the patients
presented with poor diabetic control in diabetic ketoacidosis and 80% had
persistent dyslipidaemia.
Gianfrate and Ferraris reported a different outcome. They described a
diabetic, non-alcoholic who presented with ketoacidosis, pancreatitis and
moderate hyperlipaemia (347 mg/d1)(3.9 mrino1/1). Since the lipids were
moderately elevated, and unlikely to be the cause of the pancreatitis, they
propose that diabetic ketoacidosis may be a cause of pancreatitis with
secondary dyslipidaemia. 62
In another study with a similar finding, 90 patients of 100 admissions with
diabetic Ketoacidosis were examined. Of these 11 patients were found to
have pancreatitis, confirmed by CT Scan. Four of these patients were found to
have hypertriglyceridaemia(11.3 mmo1/1) on admission. The lipid abnormality
resolved with the resolution of the pancreatitis and the diabetic ketoacidosis. 59
In another study diabetes was found in 7 of 13 patients who presented with
dyslipidaemia and pancreatitis. It was not clear whether these patients had
diabetic ketoacidosis at the time and whether the dyslipidaemia resolved after
the resolution of the pancreatitis.63
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In the series by Buch et al., 7% of those with dyslipidaemic pancreatitis
eventually required therapy for diabetes 39 . Athyros et at found 5 of 17(29%) of
admissions with hypertriglyceridaemia(>11.3 mmo1/1) and pancreatitis to be
associated with uncontrolled diabetes' whereas
Fortson et al. found 72% of their group to have diabetes 8 .
Persistent and Transient lipid abnormalities 
In the dyslipidaemic group, 42(54%) had persistent lipid abnormalities and
36(46%) had transient lipid abnormalities.
Alcohol was associated with 69.4% of those with transient lipid abnormalities
as opposed to 52.4% of those with persistent lipid abnormalities.
In contrast Cameron et at reported persistent lipid abnormalities in 77.3% of
22 patients. Twenty one (94.45%) of these were associated with alcohol
consumption 24 .
Biliary pancreatitis and dyslipidaemia 
In this cohort, 10% of the dyslipidaemic pancreatitis was associated with
biliary disease.
Fortson et al. found 22% of their group had dylipidaemic pancreatitis
associated with biliary disease8 . In other studies there is scant information on
the association between biliary pancreatitis and dyslipidaemia.
Disease severity in Dyslipidaemic Pancreastitis 
Severity scoring using the Glasgow criteria, Banks clinical assessment and
ICU admission showed a trend toward more severe disease in patients with
dyslipidaemia although this did not reach statistical significance.
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Normolipaemia appeared to be protective for the development of
complications.
Fortson et al found that the severity assessment by Ranson, Apache, Banks
and Balthazar CT scan methods to be no different from historical controls.
However only 18 of 70(26%) patients were assessed for severity in the
dyslipidaemic group, making the assessment inconclusive. 8
The use of scoring systems in pancreatitis associated with dyslipidaemia has
not been previously reported and comparison between different studies is
difficult.
Mortality in dyslipidaemic pancreatitis 
In this cohort deaths in patients with dyslipidaemia and pancreatitis were
found in those who had primary dyslipidaemia(3)and those with secondary
dyslipidaemia associated with alcohol(6) with a cumulative death rate of 12%.
All the deaths were in patients with hypertriglyceridaemia with the majority,
56% in patients with mild hypertriglyceridaemia.
Athyros et at had 1 death(6%) in 17 admissions with
hypertriglyceridaemia(1000mg/d1)(11.3 mmol/L) and pancreatitis, and Fortson
et at had a mortality of 6% in their patients with dyslipidaemia and
pancreatitis 7 ' 8 . Mortality in patients with < 1000mg/d1(11.3 mmo1/1) of
hypertriglyceridaemia and patients with hypercholesterolaemia was not
alluded to in these findings'
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Conclusion 
This is the first study to assess dyslipidaemia associated with pancreatitis in
a South African population composed mostly of Indians and Africans. The
hospital prevalence of 34% in this study is comparable with the cited literature
in which lipid abnormalities were routinely assessed. The mortality of 12% is
similar to previously reported mortality rates.
The prevalence of dyslipidaemia was highest within the Indian group and
lowest in the Africans These findings have not been corroborated in other
studies which have predominantly been conducted in Caucasian populations.
Contrary to other reports, significantly elevated amylase levels, as a
confirmatory test was sufficient to arrive at a diagnosis of pancreatitis in most
of our cases.
Patients with familial dyslipidaemia had recurrent episodes of pancreatitis
despite supervised medical therapy and remain problematic to manage.
There was a trend towards more severe disease in patients with
dyslipidaemia and pancreatitis.
A greater proportion of patients with diabetes had triglyceride levels above 10
mmol/l when compared to the levels with alcohol or drugs. However, all
fatalities were associated with dyslipidaemia and alcohol consumption. All the
deaths in the dyslipidaemics had hypertriglyceridaemia and this was
independent of the level. The lack of correlation between the level of
hypertriglyceridaemia and mortality has not been previously reported.
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Clinical implications 
Indian patients with an alcohol aetiology have a high prevalence of
dyslipidaemia and if this is hypertriglycaridaemia it carries a mortality risk
hence it seems reasonable strategy to measure the lipids in this clinical
category and if associated with severe disease should be actively monitored
for organ dysfunction on a daily basis daily, and the level of support escalated
accordingly.
Better managememt strategies need to be devised for the familial
dyslipidaemias as thease are recurrent despite supervised medical therapy
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Table 1: Potential causes in non alcohol/ non gallstone related pancreatitis
Aetiology
Obstruction
Ampullary or pancreatic cancers
Worms or foreign bodies obstructing the ampulla
Pancreas divisum with accessory duct obstruction
Choledochocele
Periampullary duodenal diverticulum
Hypertensive sphincter of Oddi
Toxins or drugs
Scorpion venom, organophosphorous insecticide
Drugs: azathioprine and mercaptopurine, valproic acid
oestrogens, tetracycline, metronidazole,
nitrofurantoin, pentamidine,furosemide, methyldopa




Accidental blunt abdominal trauma













Vasculitis- Systemic Lupus erythematosus,
Polyarteritis nodosa
Miscellaneous conditions
Penetrating peptic ulcer
Crohn's disease
Reye's syndrome
Idiopathic causes
